Wiener Medizinische Wochenschrift

, Volume 160, Issue 9–10, pp 225–229 | Cite as

Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy

  • Christoph Strehblow
  • Guenther Haberhauer
  • Peter Fasching
Themenschwerpunkt

Summary

Switching between different biologic agents for the treatment of rheumatoid arthritis has become a common practice even within similar substance groups. This longitudinal observational study was performed to follow the therapeutic management of patients with rheumatoid arthritis who were switched from one biologic therapy to another. We found no differences between the different biologic agents in regard to drug survival respectively efficacy, neither in the first nor in the second course of therapy. The reason to switch (side effect, lack of efficacy or loss of efficacy) did not influence the following treatment, although a lack of efficacy showed the shortest drug survival in the subsequent therapy. In conclusion, while switching between different biologic substances in rheumatoid arthritis is feasible and reasonable, the choice of substance has to be made on an individual basis.

Keywords

Rheumatoid arthritis Tumor necrosis factor Biologic therapy Switching 

Vergleich verschiedener Biologikatherapien bei Patienten mit rheumatoider Arthritis nach Versagen der Erstlinientherapie

Zusammenfassung

Der Wechsel zwischen verschiedenen Biologikatherapien hat sich zu einer gängigen Praxis bei Patienten mit rheumatoider Arthritis entwickelt. Diese longitudinale Beobachtungsstudie wurde durchgeführt, um das therapeutische Management von Patienten mit rheumatoider Arthritis, die von einer Biologikatherapie zu einer anderen umgestellt wurden, zu beobachten. Wir fanden dabei keine Unterschiede zwischen den verschiedenen Biologikasubstanzen hinsichtlich des Medikamentenüberlebens bzw. der Effektivität, weder im ersten noch im zweiten Behandlungszyklus. Der Grund zum Wechsel beeinflusste die kommende Behandlung nicht, obwohl ein Primärversagen die kürzeste Überlebensdauer der folgenden Behandlung nach sich zog. Zusammenfassend ist der Wechsel zwischen verschiedenen Biologikatherapien durchführbar und sinnvoll, die Substanzwahl muss individuell entschieden werden.

Schlüsselwörter

Rheumatoide Arthritis Tumornekrosefaktor Biologikatherapie 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lipsky PE, van der Heijde DM, St. Clair EW, et al. For the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med, 343: 1594–1602, 2000CrossRefPubMedGoogle Scholar
  2. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 340: 253–259, 1999CrossRefPubMedGoogle Scholar
  3. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum, 52: 1020–1030, 2005CrossRefPubMedGoogle Scholar
  4. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum, 41: 2196–2204, 1998CrossRefPubMedGoogle Scholar
  5. Emery P, Keystone E, Tony HP, et al. IL-6 Receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre Randomised Placebo Controlled Trial. Ann Rheum Dis, 67: 1516–1523, 2008CrossRefPubMedGoogle Scholar
  6. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med, 353(11): 1114–1123, 2005CrossRefPubMedGoogle Scholar
  7. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum, 54: 2793–2806, 2006CrossRefPubMedGoogle Scholar
  8. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis, 62: 1195–1198, 2003CrossRefPubMedGoogle Scholar
  9. Wick M, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy to infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol, 34: 353–358, 2005CrossRefPubMedGoogle Scholar
  10. Bombardieri S, Ruiz AA, Fardellone P, et al. Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology, 46: 1191–1199, 2007CrossRefPubMedGoogle Scholar
  11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 31: 315–324, 1988CrossRefPubMedGoogle Scholar
  12. Hansen KE, Hildebrand J, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol, 31: 1098–1102, 2004PubMedGoogle Scholar
  13. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol, 31: 2356–2359, 2004PubMedGoogle Scholar
  14. Gómez-Puerta JA, Sanmartí R, Rodríguez-Cros JR, et al. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis, 63: 896, 2004CrossRefPubMedGoogle Scholar
  15. Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol, 23: 795–800, 2005PubMedGoogle Scholar
  16. Gomez-Reino JJ, Carmona L; Biobadaser Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther, 8: R29, 2006CrossRefPubMedGoogle Scholar
  17. Hjardem E, Østergaard M, Pødenphant J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis, 66: 1184–1189, 2007CrossRefPubMedGoogle Scholar
  18. Buch M, Bingham S, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum, 57: 448–453, 2007CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Christoph Strehblow
    • 1
  • Guenther Haberhauer
    • 1
    • 2
  • Peter Fasching
    • 1
  1. 1.5th Department of Internal Medicine (Endocrinology and Rheumatology)Wilhelminen-HospitalViennaAustria
  2. 2.Institute of Rheumatology of the Kurstadt Baden and the Danube-University KremsBadenAustria

Personalised recommendations